Revive Therapeutics Ltd logo

Revive Therapeutics Ltd

NEW
FRA:31R (Canada)  
€ 0.0085 +0.0070 (+466.67%) Apr 7
At Loss
P/B:
7.54
Market Cap:
€ 5.38M ($ 5.90M)
Enterprise V:
€ 4.90M ($ 5.37M)
Volume:
-
Avg Vol (2M):
29.65K
Trade In:
What is a stock summary page? Click here for an overview.

Business Description

Description
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. Currently, the Company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various program.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 2.2
Equity-to-Asset 0.66
Debt-to-EBITDA -0.01
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 48.23
9-Day RSI 49.49
14-Day RSI 49.81
3-1 Month Momentum % -90.91
12-1 Month Momentum % -95

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.06
Quick Ratio 0.06
Cash Ratio 0.02

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -9.6
Shareholder Yield % 1.73

Profitability Rank

Name Current Vs Industry Vs History
ROE % -66.63
ROA % -46.93
ROIC % -27.86
3-Year ROIIC % -427.54
ROC (Joel Greenblatt) % -528800
ROCE % -65.78

GF Value Rank

Name Current Vs Industry Vs History
PE Ratio without NRI N/A
N/A
N/A
PB Ratio 7.54
EV-to-EBIT -1.44
EV-to-EBITDA -1.44
EV-to-FCF -2.93
Earnings Yield (Greenblatt) % -69.44
FCF Yield % -31.06

Financials

FRA:31R's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

Revive Therapeutics Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €)
EPS (TTM) (€) -0.004
Beta 17.49
3-Year Sharpe Ratio 0.57
3-Year Sortino Ratio 4.51
Volatility % 1529.91
14-Day RSI 49.81
14-Day ATR (€) 0.00215
20-Day SMA (€) 0.001175
12-1 Month Momentum % -95
52-Week Range (€) 0.0005 - 0.0295
Shares Outstanding (Mil) 418.56

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Revive Therapeutics Ltd Filings

Filing Date Document Date Form
No Filing Data

Revive Therapeutics Ltd Stock Events

Financials Calendars
Event Date Price (€)
No Event Data

Revive Therapeutics Ltd Frequently Asked Questions

What is Revive Therapeutics Ltd(FRA:31R)'s stock price today?
The current price of FRA:31R is €0.01. The 52 week high of FRA:31R is €0.03 and 52 week low is €0.00.
When is next earnings date of Revive Therapeutics Ltd(FRA:31R)?
The next earnings date of Revive Therapeutics Ltd(FRA:31R) is .
Does Revive Therapeutics Ltd(FRA:31R) pay dividends? If so, how much?
Revive Therapeutics Ltd(FRA:31R) does not pay dividend.

Press Release

Subject Date
No Press Release